We make science backed, all-in-one vitamins to fuel your immune health and end unnecessary illness.
Business overview
Location | London, United Kingdom |
---|---|
Social media | |
Website | www.tonichealth.co/ |
Sectors | Food & Beverage Mixed Digital/Non-Digital Mixed B2B/B2C |
Company number | 12174856 |
Incorporation date | 27 Aug 2019 |
Investment summary
Business highlights
- £94,656 revenue in last 3 months with only £9k media spend
- 49% average monthly D2C growth in the last 3 months to October
- Listed in 2000 distribution points incl. Sainsbury’s & Boots
- Featured in Telegraph and the Daily Mail with a community of 25k
Idea
Introduction
Tonic’s mission is to end unnecessary illness by championing the power of our immune system. We restore your biochemistry to boost immune health with high-dose formulas that contain scientifically backed vitamins, minerals and plants.
74% of the UK have sub-optimal vitamin D levels, which is why we needed to create a solution to address this issue. Our range of 5 immunity drinks formulated with a leading doctor have two functions:
1. Strengthen the immune system for prevention
2. Fuel the immune systems to support treatment and recovery from cold and flu.
We then paired these with tech, diagnostics, and expert advice to build deep customer relationships. You can text our nutritionist 24/7, you can check your immune health biomarkers with at-home blood testing kits through our partnership with Thriva and learn from scientists on our podcast.
Substantial accomplishments to date
-In under two years since our founder went full time, we've made over £417,000+ of sales with £94,656 revenue in from August to October this year*.
-Last 90 day repeat purchase rate to 1st November at 61% of customers with subscriber churn rate at only 5.7% in November.
-Listed in over 2,000 distribution points including Sainsbury’s, Boots, H&B, Wh Smith, Ocado, Victoria Health, Chemist Direct, Medicare and many more.
-Rate of sale matched those of leading incumbents’ Sambucol and Emergen-C**
-Conducted clinical trial measuring the performance of Tonic on immune health which showed a 26% improvement versus placebo.
-Built a community of over 25,000 followers across our socials and newsletter.
-Launched ‘The Power Within Us’ podcast – with doctors, nutritionists, and authors from all over the world joining for conversations on the power of natural health.
-Raised over £665k to date from an exceptional team of investors including an ex-president of Unilever and the founder of New Look.
-Have launched and are trading in the USA ready for strong growth in 2022.
*Based on unaudited management accounts
** Based on Nielsen data of Sainsbury’s supermarket on a weighted distribution basis showing last 6 Weeks data to April 10th 2021.
Monetisation strategy
Since day one we have taken a brand first approach with a 5-year equity partnership with And Rising (the scale-up agency of Sweaty Betty) to win customers through the power of brand.
Tonic’s multi-channel distribution strategy aims to deliver diversified revenue growth by selling our range across all key channel verticals both in the UK and USA:
- Retail and Pharmacy
- Direct-to-consumer; website and Amazon
What’s down the line? Our tech plans will allow us to develop additional intellectual property and integrations with wearable health tech to predict when consumers are about to get sick.
The immune system is everywhere. It is involved in so many processes in the body from inflammation to hay fever. This gives us a clear pipeline of NPD to drive growth.
Use of proceeds
We’ve got a great product which our customers love, and a superb team focused on driving our mission forward. Working from our proven platform with low cash burn (Q3 average £10k per month), your investment will go into four core areas designed to help us grow, while further establishing Tonic as a leading immune health brand.
1. New market investment
Support the US D2C launch and fuel growth, we need funds to support growth.
2. Growth and marketing costs in the UK
Continue building awareness & audience in the UK.
3. Team growth
Hire a head of e-commerce to support UK and US growth.
4. NPD development
Develop and launch Tonic’s first hay fever product.
Key Information
Outstanding Debt
Please note the company has an outstanding bounce back loan of £32,500 from Starling Bank accruing interest of 2.5% per year with a maturity date of 08.12.2026.
The company also owes their manufacturer approximately £18K with the agreement that this will be paid during the next production run round.
The funds raised as part of this round will not be used to repay these loans.
Share Classes
The company currently has 2 classes of shares, A Ordinary and B Ordinary. All investors in this round, including Seedrs investors, will be receiving A Ordinary shares.
Seedrs investors will receive A shares which have preferential rights over B shares. The founder has B shares which is a lower class and ensures all major business decisions need to go to the A shareholders for a vote.
Investor Perks
Please note that any discounts, rewards and/or offers listed by a company in its campaign are subject to the terms and conditions applied by that company and listed above. It is the company’s responsibility to honour such discounts, rewards and/or offers and Seedrs does not take any responsibility for them.
Open an account to get access to the team members of Tonic Health
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Only shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy shares